Barak-Shinar D, Amos Y, Bogan RK. Sleep disordered breathing analysis in a general population using standard pulse oximeter signals. Sleep Breath. 2013 Sep;l 7(3):1109-15.
Black J, Duntley SP and Bogan RK. Recent Advances in The Treatment and Management of Excessive Daytime Sleepiness. CNS Spectr. 2007 Feb;12(2 Suppl 2) 1-14.
Cairns A, Bogan R.,_Prevalence and Clinical Correlates of a Short Onset REM Period (SOREMP) during Routine PSG. Sleep. 2015 Oct 1;38(10):1575-81.
Cairns A, Poulos G, Bogan R. Who is getting tested for obstructive sleep apnea using a portable recording system? Test results from 193,221 patients. J Clin Sleep Med. 2014 Nov 15;10(11):1193-8
Colrain IM, Black J, Siegel LC, Bogan RK, Becker PM, Farid-Moayer M, Goldberg R, Lankford DA, Goldberg AN, Malhotra A multicenter evaluation of oral pressure therapy for the treatment of obstructive sleep apnea. Sleep Med. 2013 Sep;14(9):830-7.
Bogan RK, Cheray JA. Restless legs syndrome: a review of diagnosis and management in primary care. Postgrad Med. 2013 May;l25(3):99-1 l 1.
Bogan RK, Roth T, Schwartz J, Miloslavsky M. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy. J Clin Sleep Med. 2015 Apr 15;11(4):427-32.
Bogan RK. From bench to bedside: An overview of rotigotine for the treatment of restless legs syndrome. Clin Ther. 2014 Mar 1;36(3):436-55.
Bogan RK, Lee DO, Buchfuhrer MJ, Jaros MJ, Kim R, Shang G. Treatment response to sleep, pain, and mood disturbance and their correlation with sleep disturbance in adult patients with moderate-to-severe primary restless legs syndrome: Pooled analyses from 3 trials of gabapentin enacarbil. Ann Med. 2015 May;47(3):269-77.
Bogan RK, Feldman N, Emsellem HA, Rosenberg R, Lu Y, Bream G, Khayrallah M, Lankford DA. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015 Sep; 16(9): 1102-8
Bogan RK. Armodafinil in the treatment of excessive sleepiness. Expert Opin Pharmacother. 2010 Apr;l 1(6):993-1002.
Bogan RK. Effects of Restless Legs Syndrome (RLS) On Sleep. Neuropsychiatric Disease and Treatment. 2006:2(4) 513-519.
Bogan, Richard K., Fry, June M., Schmidt, Markus H., Carson, Stanley W., Ritchie, Sally Y. Ropinirole in the Treatment of Patients with Restless Legs Syndrome: A U.S.-Based Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Mayo Clinic Proceedings". January 2006; 81 (1): 17-27.
Bogan RK, Turner J. New Assessment Tools That Measure Sleep Vital Signs: The SleepMed Insomnia Index and the Sleep Matrix. Neuropsychiatric Disease and Treatment. 2007; 3(4) 509-518.
Bogan RK, Widemed's Morpheus™ Clinical Sleep Information System. Sleep and Diagnosis Therapy. 2007; 2(3) 1-2.
Bogan, Richard K., Zielinski, Mark R., Kline, Christopher E., Kripke, Daniel F., Y oungstedt, Shawn D. No Effect of 8-Week Time in Bed Restriction on Glucose Tolerance in Older Long Sleepers. J. Sleep Res., 17, 412-419, April 30, 2008.
Bogan R. Treatment Options for Insomnia-Pharmacodynamics of Zolpidem Extended-Release to Benefit Next-Day Performance. Postgraduate Medicine, September 2008, Vol. 120, Issue 3.
Bogan RK, Bornemann, M, Kushida C.et al.: XP060 Study Group Long-term Maintenance Treatment of Restless Legs Syndrome with Gabapentin Enacarbil: A Randomized Controlled Study" Mayo Clinic Proceedings: June 2010;85(6):512- 521.
Bogan, R. "Long-Term Maintenance Treatment of Restless Legs Syndrome with Gabapentin Enacarbil: A Randomized Controlled Study." Best of Sleep Medicine 2011; Annual Collection of Scientific Literature (Volume 2). Ed. Lee-Chiong, Teofilo, Amazon Books, 2001. 214.
Bogan, RK. Ropinirole treatment for restless legs syndrome. Expert Opinion on Pharmacotherapy. Vol. 9, No.4, March 2008, pp.611-623(13).
Bogan, RK. "Armodafinil in the treatment of excessive daytime sleepiness." Expert Opinion on Pharmacotherapy. Vol.11, No.4, April 2010, pp. 993- 1002(10).
Hening WA, Allen RP, Ondo WG, Walters AS, Winkelman JW, Becker P, Bogan R, Fry JM, Kudrow DB, Lesh KW, Fichtner A, Schollmayer E; "SP792 Study Group. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States." Movement Disorders. August 2010 15:25(11): 1675-1683.
Kline, C., Zielinski, M., Devlin, T., Kripke, D., Bogan, R., Youngstedt, S. "SelfReported Long Sleep in Older Adults is Closely Related to Objective Time in Bed". Sleep and Biological Rhythms: 2010: 8: 42-51.
Ray MA, Youngstedt SD, Zhang H, Robb SW, Harmon BE, Jean-Louis G, Cai B, Hurley TG, Hebert JR, Bogan RK, Burch JB. Examination of wrist and hip actigraphy using a novel sleep estimation procedure. Sleep Sci. 2014 Jun;7(2):74- 81.
Ray, MA, Hebert JR, Youngstedt SD, Zhang H, Steck SE, Bogan RK, Burch JB. The National Veteran Sleep Disorder Study: Descriptive Epidemiology and Secular Trends, 2000-2010. Sleep. 2016 Apr 12.
Rosenberg, R., Bogan, R., Armodafinil in the Treatment of Excessive Sleepiness. Nature and Science of Sleep: 2010:2:1-11.
Rosenberg, R., Bogan, R., Tiller, J., Yang, R., Youakim, J., Earl, C., Roth, T., "A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Armodafinil for Excessive Sleepiness Associated with Jet Lag Disorder" Mayo Clinic Proceedings: Web: June 7, 2010:
Roth T, Bogan RK, Culpepper L, et al. "Excessive sleepiness: under-recognized and essential marker for sleep/wake disorder management." Current Medical Research & Opinion Vol. 26, Supplement 2, 2010, S3-S27
Roth T, Bogan RK, Culpepper L, Doghramji K, Doghramji P, Drake C, Grauke JH, Knoepflmacher P, Sateia M, Silvershein D, Thorpy MI.Excessive sleepiness: under-recognized and essential marker for sleep/wake disorder management. Curr Med Res Opin. 2010 Dec;26 Suppl 2: S3-24.
Schwarz JR, Feldman NT, Bogan RK Et Al. Dosing Regimen Effects of Modafinil For Improving Daytime Wakefulness in Patients with Narcolepsy. Clin Neuropharmacol. 2003 Sep-Oct; 26(5):252-7.
Schwarz JR, Feldman NT, Bogan RK. Dose Effects ofModafinil In Sustaining Wakefulness in Narcolepsy Patients with Residual Evening Sleepiness. J Neuropsychiatry Clin Neurosci.2005 Summer; 17(3):405-12.
Youngstedt, S., Kline, C., Zielinski, M., Kripke, D., Devlin, T., Bogan, R., Wilcox, S., Hardin, J. Tolerance of Chronic 90-Minute Time-In-Bed Restriction in Older Long Sleepers. SLEEP: November 2009: 1467-1479.
Youngstedt SD, Kripke DF, Kline CE, Zielinski MR, Bogan RK. Lack of impairment in glucose tolerance: support for further investigation of sleep restriction in older long sleepers. J Sleep Res. 2010 Mar;19(1 Pt 1):116-7.
Winkelman JW, Bogan RK, Schmidt MH, Hudson JD, Derossett SE, Hill-Zabala CE. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Movement Disorders. 2011 May 24.
Wright KP Jr, Bogan RK, Wyatt JK. Shift work and the assessment and management of shift work disorder (SWD). Sleep Med Rev. 2013 Feb;l 7(1):41- 54
Thorpy MJ, Bogan RK. Update on the pharmacologic management of narcolepsy: mechanisms of action and clinical implications. Sleep Med. 2020 Apr;68 :97-109. doi: 10.1016/j.sleep.2019.09.001. Epub 2019 Sep 11. PMID: 32032921.
Bogan RK, Thorpy MJ, Dauvilliers Y, Partinen M, Del Rio Villegas R, FoldvarySchaefer N, Skowronsld R, Tang L, Skobieranda F, Sonka K. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021 Mar 12;44(3):zsaa206. doi: 10.1093/sleep/zsaa206. Erratum in: Sleep. 2021 Jul 9;44(7): Enatum in: Sleep. 2021 Nov 12;44(11): PMID: 33184650; PMCID: PMC7953213.
Dauvilliers Y, Arnulfl, Foldvary-Schaefer N, Morse AM, Sonka K, Thorpy MJ, Mignot E, Chandler P, Parvataneni R, Black J, Sterkel A, Chen D, Skobieranda F, Bogan RK. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. LancetNeurol. 2022 Jan;21(1):53-65. doi: 10.1016/Sl474-4422(21)00368- 9. PMID: 34942138.
Dauvilliers Y, Bogan RK, Arnulfl, Scammell TE, St Louis EK, Thorpy MJ. Clinical considerations for the diagnosis of idiopathic hypersomnia. Sleep Med Rev. 2022 Dec;66:101709. doi: 10.1016/j.smrv.2022.101709. Epub 2022 Oct 31. PMID: 36401976.
Dauvilliers Y, Bogan RK, Sonka K, Partinen M, Foldvary-Schaefer N, Thorpy MJ. Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution: A Lower-Sodium Alternative for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy. Nat Sci Sleep. 2022 Mar 29;14:531-546. doi: 10.2147/NSS.S279345. PMID: 35378745; PMCID: PMC8976528.
Dauvilliers Y, Sonka K, Bogan RK, Partinen M, Del Rio Villegas R, FoldvarySchaefer N, Skowronski R, Chen A, Black J, Skobieranda F, Thorpy MJ. Conection to: Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs. 2022 Jul;36(7):785-786. doi: 10.1007/s40263-022- 00933-l. Erratum for: CNS Drugs. 2022 Jun;36(6):633-647. PMID: 35764867; PMCID: PMC9259537.
Bogan R, Thorpy MJ, Winkelman JW, Dubow J, Gudeman J, Seiden D. Randomized, crossover, open-label study of the relative bioavailability and safety ofFT218, a once-nightly sodium oxybate formulation: Phase 1 study in healthy volunteers. Sleep Med. 2022 Dec;l00:442-447. doi: 10.1016/j.sleep.2022.09.011. Epub 2022 Sep 21. PMID: 36252412.
Cederberg KLJ, HanifU, Peris Sempere V, Hedou J, Leary EB, Schneider LD, Lin L, Zhang J, Morse AM, Blackman A, Schweitzer PK, Kotagal S, Bogan R, Kushida CA, Ju YS, Petousi N, Turnbull CD, Mignot E, The Stages Coho1i Investigator Group. Proteomic Biomarkers of the Apnea Hypopnea Index and Obstructive Sleep Apnea: Insights into the Pathophysiology of Presence, Severity, and Treatment Response. Int J Mol Sci. 2022 Jul 20;23(14):7983. doi: 10.3390/ijms23147983. PMID: 35887329; PMCID: PMC93 l 7550.
Bogan RK, Thorpy MJ, Dauvilliers Y, Partinen M, Del Rio Villegas R, FoldvarySchaefer N, Skowronski R, Tang L, Skobieranda F, Sonka K. Conigendum to: Efficacy and Safety of Calcium, Magnesium, Potassium, and Sodium Oxybates (Lower-Sodium Oxybate [LXB]; JZP-258) in a Placebo-Controlled, DoubleBlind, Randomized Withdrawal Study in Adults With Narcolepsy With Cataplexy. Sleep. 2021 Jul 9;44(7):zsab033. doi: 10.1093/sleep/zsab033. Enatum for: Sleep. 2021 Mar 12;44(3): PMID: 34223903; PMCID: PMC8271133.
Thorpy MJ, Arnulf I, Foldvary-Schaefer N, Morse AM, Sonka K, Chandler P, Hickey L, Chen A, Black J, Sterkel A, Chen D, Bogan RK, Dauvilliers Y. Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period< of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia. Nat Sci Sleep. 2022 Oct 26;14:1901-1917. doi: 10.2147/NSS.S369122. PMID: 36320423; PMCID: PMC9618250.
Dauvilliers Y, Sonka K, Bogan RK, Partinen M, Del Rio Villegas R, FoldvarySchaefer N, Skowronski R, Chen A, Black J, Skobieranda F, Thorpy MJ. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications. CNS Drugs. 2022 Jun;36(6):633-647. doi: 10.1007/s40263-022-00926-0. Epub 2022 May 30. Enatum in: CNS Drugs. 2022 Jul;36(7):785-786. PMID: 35635687; PMCID: PMC92 l 3292.
